X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET
Company Participants
Dan Ferry - IR
Paula Ragan - CEO
Adam Mostafa - CFO
Mark Baldry - CCO
Conference Call Participants
David Bautz - Zacks Small-Cap Research
Stephen Willey - Stifel
Leah Cann - Brookline Capital Markets
RK - H.C. Wainwright
Ed Tenthoff - Piper Sandler
Kristen Kluska - Cantor
Operator
Good morning, everyone, and welcome to X4 Pharmaceuticals Second Quarter 2024 Earnings Conference Call. [Operator Instructions] Also today's call is being recorded. [Operator Instructions]
It is now my pleasure to introduce your host, Mr. Dan Ferry from LifeSci Advisors. Dan, please go ahead.
Dan Ferry
Thank you, operator, and good morning, everyone. Thank you for joining us today. Presenting on today's call will be Dr. Paula Ragan, X4's President and CEO; and the company's Chief Financial Officer, Adam Mostafa.
Following prepared remarks, we will open up the call to your questions and will be joined by Chief Commercial Officer, Mark Baldry; Chief Medical Officer, Dr. Christophe Arbet-Engels; Chief Operating Officer, Dr. Mary DiBiase; Chief Scientific Officer, Dr. Art Taveras; and José Juves, Head of Corporate and Patient Affairs.
As a reminder, on today's call, the company will be making forward-looking statements regarding regulatory and product development and commercialization plans as well as research activities and financial projections.
These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in X4's most recent filings with the SEC, including this year's Form 10-K, which was filed on March 21, 2024 and in the company's Form 10-Q for the second quarter, which is expected to be filed later today.
I'll now turn it over to Paula Ragan. Paula?
Paula Ragan
Thanks so much, Dan, and welcome, everyone. I'll just start by saying what an incredible year we've had so far. Just a few weeks ago, we celebrated the tenth anniversary of X4. When we founded the company a decade ago, a small group of us had a vision to advance our lead asset, an orally active CXCR4 antagonist called mavorixafor, to help those with rare diseases who have few to no treatment options.
As you saw this past April, we were able to realize this vision receiving U.S. approval of mavorixafor, branded as XOLREMDI for the treatment of WHIM syndrome, a rare primary immunodeficiency. The U.S. launch of XOLREMDI is now underway, and our full commercial team is in place and WHIM patients 12 years and older are now being treated with the only approved therapy targeting the underlying cause of their disease. Sales guidance on XOLREMDI will come at a future point. However, today, I'd like to highlight our strong launch progress.